Schizophrenia is recognized to be a highly heterogeneous disease at various levels, from
genetics to clinical manifestations and treatment sensitivity. This heterogeneity is also …

Schizophrenia has been primarily associated with dopamine dysfunction, and treatments
have been developed that target the dopamine pathway in the central nervous system …

Parvalbumin inhibitory interneurons (PVIs) are crucial for maintaining proper
excitatory/inhibitory balance and high-frequency neuronal synchronization. Their activity …

A growing body of evidence has emerged demonstrating a pathological link between
oxidative stress and schizophrenia. This evidence identifies oxidative stress as a …

Blood–brain barrier pathology is recognised as a central factor in the development of many
neurological disorders, but much less is known about the role of the blood–brain barrier in …

Schizophrenia is a very complex syndrome involving widespread brain multi-
dysconnectivity. Schizophrenia is marked by cognitive, behavioral, and emotional …

Schizophrenia is associated with increased levels of oxidative stress, as reflected by an
increase in the concentrations of damaging reactive species and a reduction in anti-oxidant …

The dopamine system is unique among the brain's modulatory systems in that it has discrete
projections to specific brain regions involved in motor behaviour, cognition and emotion …

Objective Antipsychotic effects of immunomodulating drugs have been suggested; however,
a thorough, comprehensive meta-analysis on the effect and safety of anti-inflammatory add …

Early detection and intervention in schizophrenia requires mechanism-based biomarkers
that capture neural circuitry dysfunction, allowing better patient stratification, monitoring of …